Dr. Falk Pharma – Innovation drives everything
As a research-based family business with global presence, we focus on the development and distribution of innovative medicines that improve patients’ health and well-being. For over 60 years.
Our focus: To enable relief, well-being, more ease of movement and confidence in everyday situations for millions of people with inflammatory bowel disease as well as digestive and metabolic problems. With the best possible therapies.
Falk Foundation provides a platform for experts in the fields of gastroenterology and hepatology to meet and communicate with one another.
What’s happening at Dr. Falk Pharma? Visit our Newsroom and follow us on social media for the latest news, press releases, clinical trial announcements, upcoming events and more from Dr. Falk Pharma.
To Develop First-in-Class Celiac Disease Therapy
Information for patients
Information for health care professionals
Get informed on various diseases of the liver, the biliary tract, the intestinal tract as well as the esophagus with details on symptoms, course of the disease, diagnosis and treatment options.
Eosinophilic esophagitis is a rare disease of the esophagus involving chronic inflammation as well as difficulty and pain swallowing. The symptoms of the disease seriously affect quality of life. As the disease is progressive, long-term treatment is necessary.
Microscopic colitis consists of two conditions called lymphocytic colitis and collagenous colitis. It is an inflammatory bowel disease and primarily impacts the large intestine. Microscopic colitis can only be diagnosed by examining tissue samples under a microscope, colonoscopy findings are typically normal.
Primary biliary cholangitis (PBC) is a chronic autoimmune disease in which the small bile ducts are damaged by inflammation. Without adequate treatment, this inflammation may eventually spread to the tissue of the liver and even cause cirrhosis. PBC affects women much more often than men.